|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC28
|
|
gptkbp:brand
|
gptkb:Cyramza
|
|
gptkbp:CASNumber
|
945721-28-8
|
|
gptkbp:chemicalFormula
|
C6368H9804N1692O1992S46
|
|
gptkbp:contraindication
|
hypersensitivity to ramucirumab
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:firstApprovedIndication
|
advanced gastric cancer
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ramucirumab
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:VEGFR-2
|
|
gptkbp:mechanismOfAction
|
VEGFR-2 antagonist
|
|
gptkbp:molecularWeight
|
146 kDa
|
|
gptkbp:monoclonalAntibodyType
|
human IgG1
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
bleeding
fatigue
hypertension
proteinuria
|
|
gptkbp:UNII
|
3X2Q1FCQ6K
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
colorectal cancer
hepatocellular carcinoma
gastric cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|